Background
The microphthalmia-associated transcription factor (MITF) is a member of the basic helix-loop-helix leucine zipper transcription factor family, which plays a central role in the differentiation of neural crest-derived melanocytes, optic cup-derived retinal pigment epithelial cells, bone marrow-derived mast cells and osteoclasts and natural killer cells [
1‐
5]. Mutations in MITF are associated with auditory-pigmentary syndromes such as Waardenburg syndrome [
6] and Tietz syndrome [
7,
8] and result in hearing loss and depigmentation of the hair and skin.
The MITF gene is expressed in different isoforms that are under the control of distinct promoters. At least eight isoforms of human MITF with different N-termini are known, MITF-A[
9], MITF-B[
10], MITF-C[
11], MITF-D[
12], MITF-E[
13], MITF-H[
14], MITF-J [
15] and MITF-M[
16], and are derived from alternative splicing of a unique first exon. They all share the common downstream exons from 2 to 9. All isoforms share important functional domains including the transactivation domain, basic domain, and helix-loop-helix and leucine-zipper domain (b-HLH-LZ). Distinct isoforms may possess cell-specific functions. For example, MITF-M is exclusively expressed in melanocyte/melanoma cells and serves as the master gene for melanocyte development, survival and differentiation.
Several studies provide evidence that MITF serves as an oncogene in human melanoma. MITF amplification was found in 15-20% of metastatic melanoma, and is associated with decreased 5-year survival [
17]. In addition, transformation of immortalized human melanocytes occurred through the cooperation of MITF and activated BRAF (
V600E) [
17].
The diagnosis of metastatic melanoma most often relies on S100 and HMB-45 melanoma biomarkers [
18]. However, S100 is highly sensitive but not very specific as it also stains other nonmelanoma cancers. In contrast, HMB-45 is highly specific for melanoma but not very sensitive as it may miss a significant of melanoma cases. Therefore, the combination of both S100 and HMB-45 is often used to improve their diagnostic utility [
18]. MITF has been shown to be superior to the S100 and HMB-45 combination in both sensitivity and specificity in the diagnosis of melanoma [
18].
One of the most difficult decisions in the treatment of melanoma is whether a particular patient needs adjuvant therapy. Current approaches to adjuvant therapy in melanoma, including the use of high dose interferon-α, are associated with significant toxicity but with modest benefits. Therefore, it is important to have ways of identifying which patients are at higher risk of relapse and, therefore, may benefit from adjuvant therapy. One of the strategies that have been widely studied is the detection of circulating tumour cells, using a variety of molecular biomarkers. The most commonly used markers are the melanoma/melanocyte tissue-differentiation antigens, including tyrosinase and melanoma-associated antigen recognized by T cells (MART-1). However, the lower than expected frequency of detection of circulating tumor cells using these assays may limit their clinical utility [
19]. Unlike other biomarkers in melanoma, MITF is expressed at various levels in almost all melanoma specimens [
18,
20]. This is most probably due to its essential function in the survival of the melanocyte linage [
18,
20]. In addition, MITF detection after treatment was a significant independent prognostic factor for relapse-free and overall survival [
21]. Therefore, MITF or MITF isoforms have the potential of being an important biomarker for melanoma.
Here we report a novel splicing variant of MITF-M, which we named MITF-Mdel. This variant was cloned from the human melanoma cell line 624 mel. Compared with wild-type MITF-M, MITF-Mdel has two in-frame deletions. The 56-amino acid deletion from V32 to E87 in exon 2 has not been previously reported in human. The 6-amino acid deletion, ACIFPT, from A187 to T192 of MITF-M in exon 6 has been previously reported in MITF-A, -D and -H isoforms [
1,
4,
5]. We found that MITF-Mdel was widely expressed in normal human melanocytes and melanoma cell lines as well as primary melanoma tissues, but was almost undetectable in non-melanoma cancer cell lines and pheriperal blood mononuclear cell (PBMC) from healthy donors. Our finding showed that MITF-Mdel expression is melanocyte/melanoma specific and thus potentially a valuable candidate biomarker for melanoma.
Methods
Cancer cell lines
All cell lines, including 31 melanoma, five glioma, four breast, two colon, one ovarian, one sarcoma, and one kidney cancer cell lines, in this study were grown in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum and 100 units/ml penicillin-streptomycin Sigma-Aldrich (MO, USA). Normal human melanocytes (NHEM) were grown in Melanocyte Cell Basal Medium-4 with growth supplements (Clonetics MGM-4™ BulletKit (CC-3249), Cambrex, NJ, USA). The cells were harvested for RNA isolation when they were approximately 70-80% confluent and in healthy condition.
Blood and frozen melanoma tissue samples
PBMC from 20 healthy donors and frozen primary melanoma tissue samples were used in this study. PBMC was isolated from normal donors' buffy coats using a standard density gradient centrifugation method (Ficoll, Invitrogen, CA, USA). Blood samples and 21 frozen melanoma tissue samples were used for RNA isolation using an RNA extraction kit (RNeasy Total RNA, Qiagen, CA, USA), following the manufacture's instructions. Buffy coats from anonymous health donors were obtained from the regional American Red Cross blood bank. All melanoma tissue samples were cryopreserved within 10 min of surgical excision in liquid nitrogen and stored within the Tissue Procurement Laboratory of the Moffitt Cancer Center as described previously [
22].
Total RNA was isolated from human melanoma cell line 624 mel and treated with RNase-free DNase I for 30 min. RT was performed simultaneously with oligo (dT) with first strand cDNA synthesis kit (Amersham Biosciences, NJ, USA). MITF-M primer design was based on published sequence of human MITF mRNA [
17]. The full-length human MITF-M cDNA, which was isolated using the forward primer 5'-gcagatctatgctggaaatgctagaatataat-3' and reverse primer 5'-gaattcacaagtgtgctccg-3', was cloned into pCDNA3.1/V5-his topo vector (Invitrogen, CA, USA). After restriction enzyme digestion screening, two types of human MITF-M constructs were identified based on agarose gel analysis.
DNA sequencing
Sequencing of the isolated human MITF-M clones was performed by the Biotechnological Laboratory Core Facility at Northwestern University. Searches for sequence homology were performed with the GeneBank database using the BLAST algorithm.
Expression analysis by RT-PCR and quantitative PCR (qPCR)
Total RNA was extracted from the three NHEMs, 31 melanoma cell lines, 21 frozen melanoma tissue samples (Frtu), 18 blood samples (PBMC) from healthy donors, and 12 non-melanoma cancer cell lines, including three breast, five glioma, one sarcoma, two kidney and one ovarian cancer cell lines using an RNA extraction kit (RNeasy Total RNA, Qiagen, CA, USA) according to the instructions. Total RNA was treated with DNase I (Promega, WI, USA) to avoid residual genomic DNA contamination. First-strand cDNA was synthesized using a First-Strand Synthesis system (ABgene, Epsom, UK) for regular RT-PCR reaction. Wild type MITF-M was amplified using primer pairs 5'-ttatagtaccttctctttgccagtcc-3' (human MITF-M specific forward primer) and 5'-cttataaaatccctctttttcacagttgga-3' (reverse). Deletion isoform, MITF-Mdel, was amplified using the same MITF-M specific forward primer and the MITF-Mdel specific reverse primer 5'-cttataaaatccctgccgttgg-3'. The cDNA for qPCR was obtained using high capacity cDNA archive kit (Applied Biosystems, CA, USA) according to the instructions. qRT-PCR was performed using the Bio-Rad iQ5 real time PCR machine coupled with SYBR Green chemistry (Applied Biosystems, CA, USA). The primers are listed in Table
1. All PCR reactions were in 25 μL of total volume containing 12.5 μL of SYBR green PCR master mix, 40 ng cDNA, 300 nM of each primer. All amplifications were done in triplicate for each sample and repeated once. The thermal cycling was 10 min at 95°C, followed by 40 cycles at 95°C for 15 s, at indicated annealing temperature for each gene in Table
1 for 20 s, and at 72°C for 30 s. The specificity of amplification was monitored using the dissociation curve of the amplified product. Relative expression of the target genes was calculated using delta Ct method, and 624 mel was used as a normalization control.
Table 1
Primer sequences for mRNA analysis by real-time polymerase chain reaction.
GADPH | F: 5'-cgagatccctccaaaatcaa-3'; | 170 | 60 |
| R: 5'-ttcacacccatgacgaacat-3' | | |
MITF-M | F: 5'-ttatagtaccttctctttgccagtcc-3' | 146 | 52 |
| R: 5'-gtttatttgctaaagtggtagaaaggtact-3' | | |
MITF-Mdel | F: 5'-ttatagtaccttctctttgccagtcc-3'; | 120 | 52 |
| R: 5'-cttataaaatccctgccgttgg-3' | | |
Statistical analysis
Quantitative PCR data were expressed as median. The Student t-test was used in the analysis. Frequency rate was analysed by chi square test. P < 0.05 was considered statistically significant.
Discussion
In this report, MITF-Mdel, a novel melanocyte/melanoma-specific isoform of MITF-M, was cloned from the human melanoma cell line 624 mel. The predicted MITF-Mdel protein contains two in frame deletions, 56- and 6- amino acid deletions in exon 2 (from V32 to E87) and exon 6 (from A187 to T192), respectively. The former deletion had not been previously reported. MITF-Mdel was widely expressed in melanocytes, melanoma cell lines and tissues, but almost undetectable in non-melanoma cell lines or PBMC from healthy donors. Both isoforms were expressed significantly higher in melanoma tissues than in cell lines. Two of 31 melanoma cell lines expressed only one isoform or the other. As seen in Figure
4, the medians of relative expression of MITF-M and MITF-Mdel by qRT-PCR are comparable. Therefore, MITF-Mdel seems to be a common isoform in melanoma. At this time, we do not know if there are differences in the relative amounts of each isoform in melanocytes versus primary melanoma versus metastatic melanoma. By correlating the differential expression of these MITF-M isoforms in primary and metastatic melanoma tissues with progression free survival and overall survival in future studies, we may be able to validate the utility of MITF-Mdel as a biomarker.
We analyzed the sequence of MITF-Mdel and the 168-bp deletion in exon 2 and found a cryptic splice donor site 'GTAAA' [
23] at the beginning of the 168-bp deletion. The last nucleotide of the 168-bp deletion is at the exon-intron boundary and can be considered as the acceptor site. This may provide a mechanistic explanation for the generation of MITF-Mdel splice variant. In addition, human MITF-M mRNA with an 18-bp deletion has been shown to result from alternative splicing using two acceptor sites located at the 5'end of exon 6 [
24].
Similar to MITF-M, MITF-Mdel is driven by the M promoter and contains the transcriptional activation domain, the b-HLH-LZ domain and the serine-rich region. Whether the 168-bp deletion in exon 2 of MITF-Mdel has any phenotypic or functional consequence is not known at this time. Since serine 73 (Ser73), which is phosphorylated by mitogen activated protein kinase cascade, is located in exon 2B of the MITF gene, the newly discovered deletion from V32 to E87 effectively removes this phosphorylation site in MITF. Phosphorylation does not seem to affect accumulation of MITF in the nucleus [
25]. However, mutation at Ser73 has been shown to reduce MITF's transcriptional activity on the tyrosinase promoter [
25,
26]. Other recent studies did not support the essential role of Ser73 or of exon 2 in the function of MITF. The serine to alanine mutation (Ser73Ala) did not alter the phenotype of the mutant mice [
27]. In addition, deletion of exon 2 did not affect the function of MITF [
28].
Melanoma cell line 1973 carries only the MITF-Mdel isoform and not the wild-type MITF; whereas melanoma cell line 624 carries both isoforms (Figure
3). From our previous study, it seems that MITF is still functional in 1973 mel. Downstream target genes for MITF, including tyrosinase, tyrosinase-related protein (TRP)-2, gp100, and MART-1, were expressed at comparable levels as those expressed in 624 mel [
29].
Since adjuvant treatments for melanoma may have limited benefits but much potential toxicity, the ability to identify patients at high risk for recurrence is essential in the development of an effective adjuvant therapy. A highly sensitive RT-PCR and real-time quantitative RT-PCR offer a platform for monitoring circulating melanoma cells to potentially predict melanoma prognosis and identify high-risk patients for further treatment.
Tyrosinase, MART-1, and gp100 are melanocyte/melanoma-differentiation antigens that are frequently expressed in melanoma cells and not in non-melanoma tumours. In one study, circulating tyrosinase and MART-1 mRNA was detected in only 77% and 54%, respectively in these patients [
30]. MITF-M is another melanocyte/melanoma-specific marker that has been used to detect circulating tumour cells. In a recent study, MITF expression by quantitative RT-PCR was almost undetectable in PBMC of healthy blood donors, as in our study. However, it was detected in 86% of melanoma tissue samples. The rate of circulating MITF detection was higher with increasing melanoma stages. MITF detection after treatment was a significant independent prognostic factor for relapse-free and overall survival [
21].
Conclusions
The novel isoform MITF-MDel was widely expressed in melanocytes, melanoma cell lines and tissues, but almost undetectable in non-melanoma cell lines or PBMC from healthy donors, and may serve as a potential candidate biomarker for diagnostic and follow-up purposes in melanoma.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
YW cloned the MITF-Mdel gene, investigated its expression profiling via RT-PCR and qPCR and drafted the manuscript. SR isolated PMBC from healthy donors' blood. SL carried out the RNA extraction. AR contributed melanoma tissue samples. HK participated in the design of the study and interpretation of the data, and helped to draft the manuscript. All authors read and approved the final manuscript.